Gross Profit Analysis: Comparing Pfizer Inc. and MiMedx Group, Inc.

Pfizer vs. MiMedx: A Decade of Gross Profit Trends

__timestampMiMedx Group, Inc.Pfizer Inc.
Wednesday, January 1, 201410555800040028000000
Thursday, January 1, 201516709400039203000000
Friday, January 1, 201621260800040495000000
Sunday, January 1, 201728592000041306000000
Monday, January 1, 201832272500042399000000
Tuesday, January 1, 201925617400041531000000
Wednesday, January 1, 202020890400033216000000
Friday, January 1, 202121533200050467000000
Saturday, January 1, 202221952500065986000000
Sunday, January 1, 202326684300028809000000
Monday, January 1, 202445776000000
Loading chart...

Igniting the spark of knowledge

Gross Profit Trends: Pfizer Inc. vs. MiMedx Group, Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of key players is crucial. This analysis delves into the gross profit trends of Pfizer Inc. and MiMedx Group, Inc. from 2014 to 2023. Over this period, Pfizer's gross profit exhibited significant fluctuations, peaking in 2022 with a remarkable 65% increase compared to 2020. However, 2023 saw a sharp decline of over 56%, highlighting the volatility in the market. In contrast, MiMedx Group, Inc. demonstrated a more stable growth trajectory, with gross profits increasing by approximately 153% from 2014 to 2023. This steady rise underscores MiMedx's resilience and strategic positioning in the market. As the pharmaceutical sector continues to face challenges and opportunities, these insights provide a window into the financial dynamics shaping the industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025